Metastatic Renal Cell Cancer Treated With Antiangiogenic Therapy Monitoring by 18F-FDG PET/CT

ABSTRACTRenal cell carcinoma (RCC) is resistant to chemotherapy and radiotherapy in most cases, and surgery is the preferred option in patients with local tough advanced disease. Even in metastatic RCC, patient survival has been reported to improve after surgery. Considering the importance of angiog...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical nuclear medicine 2015-11, Vol.40 (11), p.910-911
Hauptverfasser:	García Garzon, J.R, Bassa, Pere, Llinares, Elena, Soler, Marina, Moragas, Merce, Riera, Eduard
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Angiogenesis Inhibitors - therapeutic use Carcinoma, Renal Cell - diagnostic imaging Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - pathology Female Fluorodeoxyglucose F18 Humans Kidney Neoplasms - diagnostic imaging Kidney Neoplasms - drug therapy Kidney Neoplasms - pathology Middle Aged Multimodal Imaging Neoplasm Metastasis Positron-Emission Tomography Radiopharmaceuticals Tomography, X-Ray Computed
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	ABSTRACTRenal cell carcinoma (RCC) is resistant to chemotherapy and radiotherapy in most cases, and surgery is the preferred option in patients with local tough advanced disease. Even in metastatic RCC, patient survival has been reported to improve after surgery. Considering the importance of angiogenesis in RCC pathogenesis, new inhibitors of vascular endothelial growth factor pathway show promising results. Imaging monitoring with F-FDG PET/CT may allow selecting the appropriateness and right time to implement these drugs, according to disease outcome.
ISSN:	0363-9762 1536-0229
DOI:	10.1097/RLU.0000000000000927